AR001830A1 - Terapia genetica por medio del uso de vectores adenovirales - Google Patents
Terapia genetica por medio del uso de vectores adenoviralesInfo
- Publication number
- AR001830A1 AR001830A1 AR33636396A AR33636396A AR001830A1 AR 001830 A1 AR001830 A1 AR 001830A1 AR 33636396 A AR33636396 A AR 33636396A AR 33636396 A AR33636396 A AR 33636396A AR 001830 A1 AR001830 A1 AR 001830A1
- Authority
- AR
- Argentina
- Prior art keywords
- replication
- gene
- therapeutic
- specific
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Abstract
Esta invención proporciona un método para tratar el cáncer administrando un vector adenoviral competente para la replicación que comprende un genterapéutico y una región reguladora de gen específico de la enfermedad operativamente conectadoa un gen de replicación específico de la enfermedad.El vector adenoviral apuntado, competente para la replicación, se replica preferentemente en las células tumorales luego de su activación de la regiónreguladora del gen específico tumoraltran sportado por el vector adenoviral competente para la replicación. Esta invención permite, por primera vez, elapuntar un gen terapéutico para tratar el cáncer utilizando pequenas cantidades de vectores virales que selectivamente se replicanpara l iberar dosisterapéuticas del gen terapéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/433,798 US20030026789A1 (en) | 1995-05-03 | 1995-05-03 | Gene therapy using replication competent targeted adenoviral vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
AR001830A1 true AR001830A1 (es) | 1997-12-10 |
Family
ID=23721566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR33636396A AR001830A1 (es) | 1995-05-03 | 1996-04-30 | Terapia genetica por medio del uso de vectores adenovirales |
Country Status (8)
Country | Link |
---|---|
US (4) | US20030026789A1 (es) |
EP (1) | EP0827546A2 (es) |
JP (1) | JPH11506315A (es) |
AR (1) | AR001830A1 (es) |
AU (1) | AU5723696A (es) |
CA (1) | CA2218390A1 (es) |
WO (1) | WO1996034969A2 (es) |
ZA (1) | ZA963434B (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698443A (en) * | 1995-06-27 | 1997-12-16 | Calydon, Inc. | Tissue specific viral vectors |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
US6676935B2 (en) | 1995-06-27 | 2004-01-13 | Cell Genesys, Inc. | Tissue specific adenoviral vectors |
US7011976B1 (en) | 1997-03-03 | 2006-03-14 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
US6197293B1 (en) | 1997-03-03 | 2001-03-06 | Calydon, Inc. | Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof |
US6254862B1 (en) * | 1997-03-03 | 2001-07-03 | Calydon, Inc. | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof |
US7087582B1 (en) | 1995-09-26 | 2006-08-08 | Regents Of The University Of Michigan | Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21 |
US6403370B1 (en) * | 1997-02-10 | 2002-06-11 | Genstar Therapeutics Corporation | Oncolytic/immunogenic complementary-adenoviral vector system |
WO1998039467A2 (en) * | 1997-03-03 | 1998-09-11 | Calydon, Inc. | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof |
EP1905837A1 (en) * | 1997-03-03 | 2008-04-02 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
US6432700B1 (en) * | 1997-03-03 | 2002-08-13 | Cell Genesys, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
EP1007715A2 (en) * | 1997-03-03 | 2000-06-14 | Calydon, Inc. | Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
CA2282708A1 (en) * | 1997-03-03 | 1998-09-11 | Calydon, Inc. | Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof |
IL132596A0 (en) * | 1997-06-04 | 2001-03-19 | Oxford Biomedica Ltd | Vector |
US7276488B2 (en) | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
EP0945507A1 (de) * | 1998-03-27 | 1999-09-29 | Boehringer Mannheim Gmbh | Tumorspezifische Expressionskontrollregion und deren Verwendung |
US6900049B2 (en) | 1998-09-10 | 2005-05-31 | Cell Genesys, Inc. | Adenovirus vectors containing cell status-specific response elements and methods of use thereof |
WO2000018240A1 (en) | 1998-10-01 | 2000-04-06 | University Of Southern California | Gene delivery system and methods of use |
US6495130B1 (en) | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
GB9906815D0 (en) | 1999-03-24 | 1999-05-19 | Isrec | Anti-neoplastic viral agents |
KR100636578B1 (ko) | 1999-04-02 | 2006-10-19 | 히사미쓰 세이야꾸 가부시키가이샤 | 치료용 유전자 발현 염기서열 및 유전자 치료용 약제 |
AU767904B2 (en) * | 1999-05-12 | 2003-11-27 | Uab Research Foundation, The | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
US20040175362A1 (en) | 1999-05-12 | 2004-09-09 | Curiel David T. | Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
WO2001023004A1 (en) * | 1999-09-30 | 2001-04-05 | The Trustees Of The University Of Pennsylvania | Replication selective adenoviruses for use in cancer therapy |
US7396679B2 (en) * | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
ES2288488T3 (es) * | 1999-11-15 | 2008-01-16 | Onyx Pharmaceuticals, Inc. | Adenovirus oncoliticos. |
JP2003515323A (ja) | 1999-11-18 | 2003-05-07 | オックスフォード バイオメディカ(ユーケイ)リミテッド | 抗 体 |
US7048920B2 (en) * | 2000-03-24 | 2006-05-23 | Cell Genesys, Inc. | Recombinant oncolytic adenovirus for human melanoma |
WO2002068627A2 (en) | 2001-02-23 | 2002-09-06 | Novartis Ag | Vector constucts |
JP2002335965A (ja) | 2001-05-14 | 2002-11-26 | Japan Science & Technology Corp | 細胞特異的発現複製ベクター |
GB0117198D0 (en) * | 2001-07-13 | 2001-09-05 | Btg Int Ltd | Anti-neoplastic viral agents |
US7364727B2 (en) * | 2002-07-22 | 2008-04-29 | Cell Genesys, Inc. | Metastatic colon cancer specific promoter and uses thereof |
WO2004042025A2 (en) | 2002-11-01 | 2004-05-21 | Cell Genesys, Inc. | Cell-specific adenovirus vector comprising ebv-specific promoter |
US20050097066A1 (en) * | 2003-10-31 | 2005-05-05 | Pitney Bowes Incorporated | Method and system for a mailing machine to verify the integrity of printed postage |
WO2008013918A2 (en) * | 2006-07-26 | 2008-01-31 | Myelin Repair Foundation, Inc. | Cell cycle regulation and differentiation |
EA027693B1 (ru) | 2008-09-26 | 2017-08-31 | Токаджен Инк. | Рекомбинантный репликационно-компетентный ретровирус с цитозиндезаминазной активностью для генной терапии нарушений клеточной пролиферации |
US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
US9669049B2 (en) | 2010-10-31 | 2017-06-06 | Tocagen Inc. | Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders |
KR101488395B1 (ko) | 2011-01-26 | 2015-04-29 | 연세대학교 산학협력단 | 암세포 특이적 유전자 발현을 위한 재조합 유전자발현 조절서열 |
CN102796709A (zh) * | 2011-05-27 | 2012-11-28 | 中国科学院上海生命科学研究院 | 肝癌特异性基因-病毒及其应用 |
CN102813939A (zh) * | 2011-06-10 | 2012-12-12 | 中国科学院上海生命科学研究院 | 前列腺癌特异性基因-病毒药物 |
AU2013211871B2 (en) | 2012-01-25 | 2017-12-14 | Board Of Regents, The University Of Texas System | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
CN110042086A (zh) | 2012-02-02 | 2019-07-23 | 得克萨斯州大学系统董事会 | 表达异源肿瘤相关抗原的腺病毒 |
CN104884627A (zh) | 2012-10-25 | 2015-09-02 | 托卡根公司 | 具有小型启动子盒的逆转录病毒载体 |
US9642921B2 (en) | 2012-12-20 | 2017-05-09 | Tocagen Inc. | Cancer combination therapy and recombinant vectors |
KR102089121B1 (ko) | 2013-03-14 | 2020-03-13 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 종양살상형 아데노바이러스 조성물 |
RU2679889C2 (ru) | 2013-04-18 | 2019-02-14 | Армо Байосайенсиз, Инк. | Способы применения интерлейкина-10 для лечения заболеваний и расстройств |
AU2016312510A1 (en) | 2015-08-25 | 2018-03-08 | Armo Biosciences, Inc. | Methods of using Interleukin-10 for treating diseases and disorders |
EA201890640A1 (ru) | 2015-09-04 | 2018-09-28 | Токаджен Инк. | Рекомбинантные векторы, содержащие пептид 2а |
CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
CN108699566B (zh) | 2016-02-23 | 2023-06-30 | 萨克生物研究学院 | 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达 |
CA3045892A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69417734T2 (de) * | 1993-02-16 | 1999-10-07 | Onyx Pharma Inc | Cytopathische viren zur therapie und prophylaxe der neoplasie |
ATE437232T1 (de) * | 1993-10-25 | 2009-08-15 | Canji Inc | Rekombinanter adenoviren-vektor und verfahren zur verwendung |
US5728379A (en) * | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
DE69534791T2 (de) * | 1994-11-28 | 2006-08-31 | Cell Genesys, Inc., South San Francisco | Vektoren zur gewebsspezifischen replikation |
US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
-
1995
- 1995-05-03 US US08/433,798 patent/US20030026789A1/en not_active Abandoned
-
1996
- 1996-04-30 ZA ZA9603434A patent/ZA963434B/xx unknown
- 1996-04-30 AR AR33636396A patent/AR001830A1/es not_active Application Discontinuation
- 1996-05-02 CA CA002218390A patent/CA2218390A1/en not_active Abandoned
- 1996-05-02 WO PCT/US1996/006199 patent/WO1996034969A2/en not_active Application Discontinuation
- 1996-05-02 JP JP8533509A patent/JPH11506315A/ja active Pending
- 1996-05-02 EP EP96915470A patent/EP0827546A2/en not_active Withdrawn
- 1996-05-02 AU AU57236/96A patent/AU5723696A/en not_active Abandoned
-
1998
- 1998-12-16 US US09/215,644 patent/US20010053768A1/en not_active Abandoned
-
2004
- 2004-05-12 US US10/845,489 patent/US20050002906A1/en not_active Abandoned
-
2007
- 2007-06-15 US US11/818,844 patent/US20070254357A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030026789A1 (en) | 2003-02-06 |
US20010053768A1 (en) | 2001-12-20 |
AU5723696A (en) | 1996-11-21 |
WO1996034969A2 (en) | 1996-11-07 |
CA2218390A1 (en) | 1996-11-07 |
EP0827546A2 (en) | 1998-03-11 |
US20070254357A1 (en) | 2007-11-01 |
US20050002906A1 (en) | 2005-01-06 |
ZA963434B (en) | 1997-02-03 |
WO1996034969A3 (en) | 1997-02-13 |
JPH11506315A (ja) | 1999-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR001830A1 (es) | Terapia genetica por medio del uso de vectores adenovirales | |
FR16C0028I2 (fr) | Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques | |
IL136104A0 (en) | Vector for tissue-specific replication and gene expression | |
IS4762A (is) | Samfallandi eitlaveiru genaferjukerfi og frumulínur | |
ATE255128T1 (de) | Peptid-immitierende substanzen in der krebstherapie | |
NO972373D0 (no) | Vektorer for vevs-spesifikk replikasjon | |
HK1028935A1 (en) | Treatment of neoplasms with interferon-sernsitive,clonal viruses | |
MXPA01010393A (es) | Tratamiento de neoplasmas con virus. | |
NO980218L (no) | p16 ekspresjonskonstruksjoner og deres anvendelse i kreftbehandling | |
DE69623969T2 (de) | Antitumorale 2-aminocarbonyl-1,2-bis (methylsulfonyl)-1-(substituierte) hydrazine | |
DE69730153D1 (de) | EHV-1 Vektoren | |
DK0768886T3 (da) | Endothelforingseffekter og behandling af vasospastiske lidelser | |
DK1272195T3 (da) | Anvendelse af fulvestrant til behandling af resistent brystcancer | |
PT1007717E (pt) | Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta | |
ES2174103T3 (es) | Uso de las secuencias reguladoras de wap o mmtv para expresion dirigida de genes heterologos ligados en celulas mamarias humanas, con inclusion de celulas de carcinoma mamario humano. | |
MX2023006869A (es) | Proteinas de union condicionalmente biespecificas. | |
ATE204018T1 (de) | Zellwachstumsinhibitoren | |
ES2186153T3 (es) | Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc. | |
ATE498687T1 (de) | Zellspezifischer expressions-/replikationsvektor | |
CO5170459A1 (es) | Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos | |
ATE309354T1 (de) | Replikationsprotein-a-bindendes transkriptionsfaktor (rbt1) und dessen verwendungen | |
Norris et al. | Ultraviolet light (UVL) and epidermal cytotoxicity: perspectives on three different ways that UVL may influence cytotoxic damage | |
ES2170479T3 (es) | Agente viral terapeutico que detiene el desarrollo de tumores. | |
WO2002038188A3 (de) | Verwendung der humanen lrp/mvp promotors für einen therapie-induzierbaren vektor | |
AR023380A1 (es) | Compuestos para la terapia y el diagnostico de cancer de pulmon y metodos de uso de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |